ReviewDiscover oncology2026
Extracellular vesicles as regulators of chemotherapy resistance in oral squamous cell carcinoma.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma (OSCC) continues to present formidable therapeutic challenges, with treatment outcomes compromised by elevated recurrence frequencies and diminished survival trajectories. Although contemporary multimodal therapeutic protocols have demonstrated progressive refinement, the emergence of pharmaceutical resistance constitutes a predominant barrier to successful clinical intervention. Recent investigations have illuminated the pivotal function of small extracellular vesicle (sEV) populations, with particular emphasis on exosomal populations, as critical mediators orchestrating intercellular dialogue within neoplastic microenvironments. These membrane-enclosed nanostructures have garnered substantial recognition for their integral participation in resistance mechanisms against cytotoxic therapies. The present comprehensive review systematically consolidates contemporary knowledge regarding EV-orchestrated pathways that facilitate chemoresistance in OSCC. The mechanistic landscape examined encompasses the horizontal transfer of regulatory microRNAs, active pharmaceutical extrusion processes, vesicular pH homeostatic perturbations, engagement of survival-promoting signaling networks, modulation of genomic damage repair machinery, immune system reprogramming, epithelial-mesenchymal transitional plasticity, and preservation of stem-like cancer cell populations. Through synthesis of current research advances, this manuscript endeavors to clarify the diverse functional dimensions of EVs in OSCC chemoresistance while establishing a conceptual foundation for future EV-directed therapeutic innovations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.